Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-155

I have similar numbers to SSilverstein.

in terms of the insipid share price, questioning the lack of buyers is fair, however we also need to consider the persistent flow of sells. We've effectively had a year of unrelenting selling. This would have to be caused by investors with volume, potentially including pre-IPO investors, Fiftyone Capital and investors from the $1.30 capital raise.

Arguably the persistent selling has created complacency on the buy side - there's no rush to buy when the share price is going to stay stubbornly low for the foreseeable future, as enabled by the constant supply.